Oak Harvest Investment Services Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oak Harvest Investment Services boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,277 shares of the biopharmaceutical company’s stock after purchasing an additional 66 shares during the quarter. Oak Harvest Investment Services’ holdings in Regeneron Pharmaceuticals were worth $1,229,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after purchasing an additional 39,780 shares during the last quarter. Capital World Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares during the last quarter. Putnam Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the last quarter. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $932,571,000. Finally, Morgan Stanley boosted its holdings in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $20.57 during mid-day trading on Thursday, hitting $1,024.09. The company had a trading volume of 378,341 shares, compared to its average volume of 459,242. Regeneron Pharmaceuticals, Inc. has a 52-week low of $688.52 and a 52-week high of $1,081.17. The stock’s 50 day moving average price is $992.50 and its 200-day moving average price is $954.60. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market capitalization of $112.84 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.16 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold a total of 63,208 shares of company stock valued at $62,514,142 over the last 90 days. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.